Indeed, AXL+/WNT5A+ melanoma cells are resistant to MAPK pathway inhibitors (Konieczkowski et al., 2014; Muller et al., 2014) and this might, at least in part, be due to the fact that the regulation of MITF expression is disconnected from BRAF. The gene discussed is BRAF; the disease is melanoma.